Abstract
Liver metastases are found at diagnosis in up to 25% of patients with colorectal cancer (CRC) and they appear during the first 3 years following diagnosis in another 40–50% [1]. Although liver resection is currently the only therapy producing long-term cure, at diagnosis 80% of patients are not considered to be candidates for resection because of the size, location, and extent of their disease. Radiofrequency ablation has been proposed as an alternative to surgery, but at present its effectiveness in terms of local disease control is still inferior to that of liver resection [2]. Transhepatic arterial chemoembolization (TACE) and transarterial 90Y radioembolization (TARE) are more recent techniques that have been evaluated in patients with locally advanced disease; however only preliminary data are available [3,4] and larger studies are needed to better evaluate these treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jaeck D, Bachellier F, Guiguet M et al (1997) Long term survival following resection of colorectal metastases. Br J Surg 84:977–980
Hompes D, Prevoo W, Ruers T (2011) Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging 11:23–30
Aliberti C, Fiorentini G, Muzzio PC et al (2011) Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 31:4581–4587
Bester L, Meteling B, Pocock N et al (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:96–105
Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumor response and resection rates. Ann Oncol 16:1311–1319
Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 25:1670–1676
Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417
Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–667
Van Cutsem E, Lang I, D’Haens G et al (2008) KRAS status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol 19(suppl):71O
Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47
Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019
Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635–1641
Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945
Ferrero A, Langella S, Russolillo N et al (2012) Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg [Epub ahead of print]
Yaghmai V, Miller FH, Rezai P et al (2011) Response to treatment series: part 2, tumor response assessment — using new and conventional criteria. AJR 197:18–27
Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064
Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304
Ruers TJM, Langenhoff BS, Neelman N et al (2002) Value of positron emission tomography with [f-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20:388–395
Fernandez F, Debrin JA, Linehan DC et al (2004) Five year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with 18-fluorodeoxyglucose (FDG-PET). Ann Surg 240:438–450
Shanbhogue AK, Karnad AB, Prasad SR (2010) Tumor Response Evaluation in oncology: current update. J Comput Assist Tomogr 34:479–484
Lubezky N, Metser U, Geva R et al (2007) The role and limitations of 18-fluoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11:472–478
Suzuky C, Jacobson H, Hatschek T et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329–344
Chun YS, Vauthey J, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344
Tochetto SM, Rezai P, Rezvani M et al (2010) Does multidetector CT attenuation change in colon cancer liver metastases treated with 90 Y help predict metabolic activity at FDG PET? Radiology 255:164–172
Pauls S, Gabelmannb A, Heinzc W et al (2009) Liver perfusion with dynamic multidetectorrow computed tomography as an objective method to evaluate the efficacy of chemotherapy in patients with colorectal cancer. Clin Imaging 33:289–294
Sun Y, Cui Y, Tang L et al (2011) Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. AJR 197:23–29
Cui Y, Zhang XP, Sun YS et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900
Marugami N, Tanaka T, Kitano S et al (2009) Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Intervent Radiol 32:638–646
Wybranski C, Zeile M, Löwenthal D et al (2011) Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases. Radiat Oncol 6:43
Dudeck O, Zeile M, Wybranski C et al (2010) Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 20:2699–706
Vriens D, van Laarhoven HWM, van Asten JJA et al (2009) Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA — Enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med 50:1777–1784
Vriens D, de Geus-Oei LF, Heerschap A et al (2011) Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clin Colorectal Cancer 10:E1–E5
Hirashima Y, Yamada Y, Tadeishi U et al (2011) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer Jul 21, 2011. doi: 10.1002/ijc.26282. [Epub ahead of print]
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Capussotti, L., Viganò, L., Leone, F., Campanella, D. (2012). Liver Metastases in Colon Cancer. In: Aglietta, M., Regge, D. (eds) Imaging Tumor Response to Therapy. Springer, Milano. https://doi.org/10.1007/978-88-470-2613-1_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2613-1_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2612-4
Online ISBN: 978-88-470-2613-1
eBook Packages: MedicineMedicine (R0)